Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:17:22 EDT Fri 18 Jul 2025
Enter Symbol
or Name
USA
CA



Q:RLAY - RELAY THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RLAY - Q0.13.40·3.620.53.50-0.15-4.11,862.16,1148,2793.66  3.72  3.5010.72  1.77519:47:57Jun 1115 min RT 2¢

Recent Trades - Last 10 of 8279
Time ETExPriceChangeVolume
19:47:57Q3.505-0.14510
19:47:57Q3.50-0.1520
19:31:26Q3.59-0.0610
19:30:46Q3.59-0.0610
19:28:36Q3.45-0.20300
16:04:16Q3.50-0.151
16:04:02Q3.50-0.151
16:02:30Q3.50-0.1544
16:02:06Q3.50-0.152,747
16:01:51Q3.50-0.15353

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-11 16:05U:RLAYNews ReleaseRelay Therapeutics Appoints Claire Mazumdar, Ph.D., to Board of Directors
2025-06-02 07:00U:RLAYNews ReleaseRelay Therapeutics Announces Updated Data for RLY-2608 + Fulvestrant Further Demonstrating Clinically Meaningful Progression Free Survival at ASCO 2025
2025-05-29 16:05U:RLAYNews ReleaseRelay Therapeutics to Participate in Two Upcoming Investor Conferences in June
2025-05-08 16:06U:RLAYNews ReleaseRelay Therapeutics to Participate in Two Upcoming Investor Conferences
2025-05-05 16:05U:RLAYNews ReleaseRelay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
2025-04-28 16:06U:RLAYNews ReleaseRelay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
2025-02-26 16:05U:RLAYNews ReleaseRelay Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
2025-02-24 16:06U:RLAYNews ReleaseRelay Therapeutics to Participate in Two Upcoming Investor Conferences
2025-02-19 16:06U:RLAYNews ReleaseRelay Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights on February 26, 2025
2025-01-07 16:05U:RLAYNews ReleaseRelay Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
2024-12-11 06:00U:RLAYNews ReleaseRelay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival
2024-12-09 16:06U:RLAYNews ReleaseRelay Therapeutics to Present Updated Clinical Data on RLY-2608 in HR+/HER2- Breast Cancer at 2024 San Antonio Breast Cancer Symposium
2024-12-03 08:01U:RLAYNews ReleaseElevar Therapeutics and Relay Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
2024-12-03 08:00U:RLAYNews ReleaseRelay Therapeutics and Elevar Therapeutics Announce Exclusive Global Licensing Agreement for Lirafugratinib in FGFR2-Driven Cholangiocarcinoma and Other Solid Tumors
2024-11-07 16:05U:RLAYNews ReleaseRelay Therapeutics to Participate in Upcoming Investor Conferences
2024-11-06 16:05U:RLAYNews ReleaseRelay Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Highlights
2024-10-30 16:05U:RLAYNews ReleaseRelay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
2024-09-10 20:22U:RLAYNews ReleaseRelay Therapeutics Announces Pricing of Public Offering of Common Stock
2024-09-09 16:34U:RLAYNews ReleaseRelay Therapeutics Announces Proposed Public Offering of Common Stock
2024-09-09 06:55U:RLAYNews ReleaseRelay Therapeutics Announces Positive Interim Data for RLY-2608 Demonstrating Clinically Meaningful Progression Free Survival